RESOURCE OVERVIEW
Manufacturing of cytotoxic and non-cytotoxic drugs in a multiproduct facility.
With the advent of more product niches and often lowered production quantities, facilities that are experienced and versatile in handling cytotoxic, highly potent, and non-cytotoxic oncology products can present a valid option when considering outsourcing. Risks for cross-contamination must be properly assessed, using state-of-the-art organization procedures, technical standards, and current industry guidance. Ultimately, patient safety is, as always, the driving force.
In this whitepaper learn how Simtra BioPharma Solutions (Simtra) leverages a risk-based approach for cross contamination.